Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1521-1540 of 1,738 trials

Immunotherapy for MSI/dMMR Tumors: Pembrolizumab Study

We are studying the effects of pembrolizumab in patients with untreated localized MSI/dMMR tumors or EBV+ gastric cancer. The goal is to see if this treatment improves outcomes before and after surgery.

MSI/dMMR Tumors and EBV+ Gastric Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

ABO-101 for Primary Hyperoxaluria Type 1

We are testing a new treatment, ABO-101, to see if it is safe and well-tolerated in people with Primary Hyperoxaluria Type 1. The study will also explore how the body reacts to the treatment.

Primary Hyperoxaluria>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteEndocrinologyNephrology

Alcohol Dependence: CBD and Naltrexone Study

We are investigating whether adding Cannabidiol to Naltrexone helps reduce alcohol cravings in people with alcohol dependence. The study also looks at its effects on mood, anxiety, and overall quality of life.

Alcohol Dependence>2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemotePsychiatry

Cancer Anorexia: ART27.13 Cannabinoid Study

We are testing a new synthetic cannabinoid to see if it helps patients with cancer gain weight and improve appetite. The study also looks at the safety and quality of life for participants.

Cancer Anorexia3-6 monthsSafety phase (I)Efficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementInternal MedicineOncology

Hidradenitis Suppurativa: IC0624 Treatment Study

We are testing a new medication, IC0624, for people with mild to moderate Hidradenitis Suppurativa. The study will help us understand its effects on symptoms, pain, and overall quality of life.

Hidradenitis Suppurativa≤3 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesDermatology

HER2-Positive Breast Cancer: New Treatment Without Chemotherapy

We are studying a combination of trastuzumab, pertuzumab, and tucatinib for patients with stage II-III HER2-positive breast cancer. The goal is to evaluate the safety and initial effectiveness of this chemotherapy-free approach.

HER2 Positive Breast Cancer1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Pancreatic Cancer: Napabucasin with Chemotherapy

We are studying how well Napabucasin works with chemotherapy for patients with metastatic pancreatic cancer after previous treatments have failed. The goal is to see if this combination improves survival and quality of life compared to standard care.

Metastatic Pancreatic CancerEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Hereditary Angioedema: BW-20805 Study

We are investigating the effects and safety of BW-20805 in adults with hereditary angioedema. The study aims to see if it can help reduce the number of HAE attacks.

Hereditary Angioedema1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesAllergologyInternal Medicine

Growth Hormone and Liver Fat Metabolism Study

We are investigating how growth hormone influences fat processing in the liver of healthy adults. Additionally, we will explore its effects in patients with acromegaly to understand fat secretion better.

AcromegalyHealthy Participants≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyHepatology

Prolonged Grief Disorder: PEX010 Treatment

We are testing a new treatment called PEX010 for people experiencing prolonged grief disorder. The study aims to see if it can significantly reduce grief symptoms and explore the effects of self-touch.

Prolonged Grief Disorder≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Non-Small Cell Lung Cancer: Drug Sequencing Study

We are investigating the best order to use two medications for patients with advanced non-small cell lung cancer that has specific mutations. This study aims to see which treatment sequence may improve outcomes for these patients.

Non-small Cell Lung Cancer (NSCLC)>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Metastatic Non-Small-Cell Lung Cancer: Tedopi Combinations

We are studying the effects of Tedopi combined with either docetaxel or nivolumab in patients with advanced lung cancer who have not responded to previous treatments. This trial aims to see if these combinations can improve survival rates and overall health.

Metastatic Non-Small-Cell Lung Cancer1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Primary Plasma Cell Leukemia: New Treatment with Bortezomib and Daratumumab

We are studying a combination of medications for people with primary plasma cell leukemia to see if it improves treatment outcomes and safety. This trial will help us understand how well this new approach works compared to current treatments.

Plasma Cell Leukemia>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesHematologyOncology

Atorvastatin for Patients with Chronic Myeloproliferative Neoplasms

We are studying whether atorvastatin can improve health markers in patients with specific blood disorders. This trial looks at its effects alongside standard treatments to see how it may help manage symptoms and disease progression.

Blood Cancer3-6 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyInternal Medicine

Lung Cancer: JNJ-90301900 with Chemoradiation

We are studying a new drug combined with standard treatments for patients with advanced non-small cell lung cancer. The goal is to see if this combination improves treatment response.

Locally Advanced Non-Small Cell Lung CancerEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Multiple Sclerosis: CBD for Sleep Quality

We are investigating whether cannabidiol (CBD) can improve sleep quality in patients with multiple sclerosis. This study aims to help those struggling with sleep issues related to their condition.

Insomnia3-6 monthsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteInternal MedicineNeurology

Lung Health: Avalyn Inhaled Antifibrotic Study

We are studying the long-term safety and effects of Avalyn's inhaled antifibrotic medications on lung function in patients who have previously participated in related trials.

Pulmonary FibrosisEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemotePulmonology

Type 2B von Willebrand Disease: BT200 Treatment Study

We are testing a new treatment called BT200 for people with Type 2B von Willebrand disease. The goal is to see if it improves blood clotting and is safe for use.

Von Willebrand's Disease Type 2B≤3 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesHematology

Cirrhosis: Carvedilol for Preventing Digestive Bleeding

We are studying whether Carvedilol can help prevent digestive bleeding in patients with cirrhosis. The trial measures its effects on liver pressure and overall tolerance over three months.

Cirrhotic Portal Hypertension3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

Uncontrolled Asthma: GSK5784283 Treatment Study

We are testing a new antibody treatment for adults with uncontrolled asthma to see if it helps improve lung function and asthma control compared to a placebo.

Asthma1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPulmonology